4.00
+0.01(+0.25%)
Currency In USD
Address
321 Summer Street
Boston, MA 02210
United States of America
Phone
857 330 4340
Website
Sector
Healthcare
Industry
Biotechnology
Employees
67
First IPO Date
July 24, 2020
| Name | Title | Pay | Year Born |
| Dr. Douglas A. Treco Ph.D. | Chief Executive Officer & Chairman | 552,017 | 1958 |
| Mr. Axel Bolte M.B.A., M.Sc. | Co-Founder, Senior Advisor & Director | 40,893 | 1972 |
| Dr. Matthew Winton Ph.D. | Senior Vice President & Chief Operating Officer | 602,100 | 1978 |
| Mr. Sanjay S. Subramanian M.B.A., M.S. | Chief Financial Officer, Head of Business Development, Principal Accounting Officer & Corporate Secretary | 607,383 | 1976 |
| Dr. Yves Sabbagh Ph.D. | Senior Vice President, Chief Scientific Officer & Chair of the Scientific Advisory Board | 0 | N/A |
| Ms. Petra Duda M.D., Ph.D. | Chief Medical Officer | 0 | N/A |
| Dr. Demetrios Braddock M.D., Ph.D. | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer | 0 | N/A |
| Mr. Stefan Riley | Director of Investor Relations | 0 | N/A |
| Ms. Gayle Gironda | Senior Vice President & Chief People Officer | 0 | N/A |
| Mr. Stephen J. Di Palma M.B.A. | Consultant | 0 | 1959 |
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.